Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy

Inclusion Criteria: * KPS performance status \>= 70% * Schedule A: all patients must have a histologically confirmed solid tumor malignancy. Schedule B: patients must have metastatic breast cancer with Her2 amplification by FISH or 3+ Her2 overexpression by immunohistochemistry ("IHC"). Patients are not required to have measurable disease for this investigation. Disease must be assessed within 28 days prior to treatment initiation * All Adverse Events of any prior chemotherapy, surgery, or radiotherapy, must have resolved to NCI CTCAE (v. 3.0) Grade \<= 2 (except for alopecia) * The following laboratory results, within 10 days of KOS-1022 administration: * Hemoglobin \>= 8.5 g/dL * Absolute neutrophils count \>= 1.5 x 10\*9\* /L * Platelet count \>= 75 x 10\*9\*/L * Serum bilirubin \<= 2 x ULN * AST and ALT \<= 2.5 x ULN * Serum creatinine \<= 2 x ULN Exclusion Criteria: * Documented hypersensitivity reaction of CTCAE Grade \>= 3 to prior therapy containing trastuzumab * Pregnant or breast-feeding women. Male patients must be surgically sterile or agree to use an acceptable method of contraception * Known active CNS metastases * Administration of any other chemotherapy, biological, immunotherapy or investigational agent (therapeutic or diagnostic) within 14 days prior to receipt of study medication. Patients should be 6 weeks from last dose of nitrosourea * Patients with Grade 2 or higher dyspnea at rest on room air; patients with other clinically significant pulmonary co-morbidity(s) that might predispose the patient to pulmonary toxicity * Moderately severe dry eye * Prior pulmonary toxic chemotherapy (e.g, bleomycin or carmustine) * Congestive heart failure, or a left ventricular ejection fraction (LVEF) * Any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient * Patients with previous malignancies unless free of recurrence for at least 5 years except cured basal cell carcinoma of the skin, carcinoma-in-situ of either the uterine cervix or urinary bladder